Element Biosciences, a trailblazer in advancing scientific discovery through groundbreaking technologies, has announced a significant milestone in its journey of innovation. The company has successfully raised over $277 million in Series D funding, underscoring its pivotal role in revolutionizing DNA sequencing and multi-omics technologies. This latest round, led by Wellington Management and supported by a consortium of esteemed investors including Samsung Electronics and Fidelity, propels Element’s cumulative funding to over $680 million.
Element Biosciences, under the leadership of CEO Molly He Ph.D., has garnered widespread acclaim for its AVITI™ platform, a compact DNA sequencer renowned for its efficiency, cost-effectiveness, and broad applicability across diverse research domains. This funding infusion is earmarked to accelerate the commercialization of AVITI™ and to launch AVITI24™, a cutting-edge instrument poised to redefine biological research by integrating state-of-the-art sequencing with cyto-profiling capabilities. This technological leap promises unprecedented insights into biological systems, facilitating advancements in precision medicine and artificial intelligence applications globally.
“We are thrilled to partner with Element Biosciences at this transformative juncture,” remarked Joshua Sommerfeld, healthcare sector lead at Wellington Management Private Investing. “Element’s commitment to democratizing genomic analysis through innovative, user-centric solutions positions them as a leader in the biotechnology landscape.”
Samsung Electronics’ Vice Chairman and CEO, Mr. Jong-Hee (JH) Han, echoed this sentiment, emphasizing Element’s pivotal role in driving the next wave of biological innovation. “Element’s dedication to enhancing the accessibility and affordability of precision medicine aligns with our vision for pioneering advancements that benefit humanity,” Mr. Han stated.
Element Biosciences has not only expanded its global footprint with a rapidly growing install base of AVITI units but has also cultivated a diverse customer portfolio spanning academia, biotechnology, and medical research. Institutions like the University of Minnesota Genomics Center have embraced AVITI for its superior performance in delivering high-quality data with unparalleled efficiency.
Reflecting on Element’s trajectory, Molly He emphasized the company’s founding mission to democratize cutting-edge biological tools. “Our journey has been driven by a steadfast commitment to innovation and collaboration,” Molly noted. “This latest funding round underscores our dedication to empowering scientists worldwide with transformative technologies.”
Editorial Opinion:
Element Biosciences stands at the vanguard of a burgeoning biotechnology revolution, poised to redefine the boundaries of scientific discovery. With its pioneering platforms, Element not only addresses the critical need for advanced genomic and multi-omics technologies but also sets a precedent for accessibility and affordability in the field. By enabling researchers to unravel the complexities of biological systems with unprecedented precision and ease, Element Biosciences is catalyzing breakthroughs that hold immense promise for enhancing human health and advancing fundamental biological understanding.
As the company continues to innovate and expand its technological capabilities, Element’s strategic vision and robust investor support signal a bright future ahead. By leveraging its expertise and ecosystem of partnerships, Element Biosciences is well-positioned to lead the charge in transforming how we approach genomic research and its applications in medicine and beyond.
Contact: If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
